Human medicines European public assessment report (EPAR): Tecartus, Brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 7, Status: Authorised

List of eligible industry stakeholder organisations

Human medicines European public assessment report (EPAR): Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune), pandemic influenza vaccine (H5N1) (live attenuated, nasal), Date of authorisation: 20/05/2016, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Spedra, avanafil, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 14, Status: Authorised

Agenda - Fourth EMA-AESGP bilateral meeting

Fifth European Medicines Agency (EMA) and the Association of the European Self-Medication Industry (AESGP) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 29 April 2024, 10:00 (CEST) to 29 April 2024, 12:00 (CEST)

Minimum inhibitory concentration (MIC) breakpoints

Minimum inhibitory concentration (MIC) breakpoints

Psychedelics and their therapeutic use - Linkedin Live interview with Steffen Thirstrup, EMA's Chief Medical Officer, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 7 May 2024, 11:30 (CEST) to 7 May 2024, 12:00 (CEST)

Human medicines European public assessment report (EPAR): Fruzaqla, fruquintinib, Status: Opinion